Akebia Therapeutics Inc.
Organization details
- Legal name
- Akebia Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AKBA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001517022
- EIN
- 20-8756903
Board of directors
-
Adrian Adams · DirectorSince 2023
- Since 2023
-
John P. Butler · Director · CEO and PresidentSince 2023
-
Leanne M. Zumwalt · DirectorSince 2023
-
Michael W. Rogers · DirectorSince 2023
-
Myles Wolf · DirectorSince 2023
-
Philip J. Vickers · DirectorSince 2026
-
Ron Frieson · DirectorSince 2023
-
Steven C. Gilman · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
68.3%
-
71.2%
-
71.4%
Board connections
4 of this board's directors also sit on 8 other boards. 8 are in the same sector.
-
Agios Pharmaceuticals Inc. Same sectorvia Cynthia Smith
-
Protara Therapeutics Inc. Same sectorvia Cynthia Smith
-
SCYNEXIS Inc. Same sectorvia Steven C. Gilman
-
Spero Therapeutics Inc. Same sectorvia Cynthia Smith
-
Talphera Inc. Same sectorvia Adrian Adams
-
Tectonic Therapeutic Inc. Same sectorvia Philip J. Vickers
-
Tvardi Therapeutics Inc. Same sectorvia Cynthia Smith
-
Vericel Corporation Same sectorvia Steven C. Gilman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $86,588
- 1 purchase by 1 insider
- Sold, last 12 months
- $962,955
- 16 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 6, 2026 | John P. Butler Director, Officer (CEO and President) | Option exercise | +350,000 | $0.63 | $220,500 |
| Jun 29, 2026 | Ostrowski Erik Officer (SVP, CFO, CBO & Treasurer) | Open-market sale | −56,019 | $1.11 | $62,181 |
| Jun 17, 2026 | Myles Wolf Director | Grant or award | +35,700 | — | — |
| Jun 17, 2026 | Cynthia Smith Director | Grant or award | +35,700 | — | — |
| Jun 17, 2026 | Michael W. Rogers Director | Grant or award | +35,700 | — | — |
| Jun 17, 2026 | Ron Frieson Director | Grant or award | +35,700 | — | — |
| Jun 17, 2026 | Leanne M. Zumwalt Director | Grant or award | +35,700 | — | — |
| Jun 17, 2026 | Adrian Adams Director | Grant or award | +35,700 | — | — |
| Mar 4, 2026 | John P. Butler Director, Officer (CEO and President) | Open-market purchase | +69,270 | $1.25 | $86,588 |
| Feb 2, 2026 | Malabre Richard C Officer (SVP, Chief Accounting Officer) | Open-market sale | −36,142 | $1.39 | $50,237 |
| Feb 2, 2026 | Grund Nicholas Officer (Chief Commercial Officer) | Open-market sale | −53,585 | $1.39 | $74,483 |
| Feb 2, 2026 | Burke Steven Keith Officer (SVP, Chief Medical Officer) | Open-market sale | −21,582 | $1.39 | $29,999 |
| Feb 2, 2026 | Rucci Carolyn M. Officer (SVP, Chief Legal Officer) | Open-market sale | −16,846 | $1.39 | $23,416 |
| Feb 2, 2026 | Ostrowski Erik Officer (SVP, CFO, CBO & Treasurer) | Open-market sale | −34,951 | $1.39 | $48,582 |
| Feb 2, 2026 | John P. Butler Director, Officer (CEO and President) | Open-market sale | −46,660 | $1.39 | $64,857 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Akebia Therapeutics Inc.
Who is the CEO of Akebia Therapeutics Inc.?
John P. Butler is Akebia Therapeutics Inc.'s CEO and President.
How many directors are on Akebia Therapeutics Inc.'s board?
Akebia Therapeutics Inc.'s board has 9 directors: Adrian Adams, Cynthia Smith, John P. Butler, Leanne M. Zumwalt, Michael W. Rogers, Myles Wolf, Philip J. Vickers, Ron Frieson and Steven C. Gilman.
Are Akebia Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Akebia Therapeutics Inc. insiders bought $86,588 of shares in 1 purchase and sold $962,955 of shares in 16 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="akebia-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.